Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

EDIT-101

Gene editing · Gene editing · developed by Editas Medicine

Phase 1/2 Most advanced trial (none active)

EDIT Developer

1 Registered trials

What is EDIT-101?

EDIT-101 is a gene-editing therapy administered via subretinal injection for Leber congenital amaurosis 10 and inherited retinal dystrophies.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Gene editing
Mechanism: Gene editing
Therapy area: Ophthalmology
Developer: Editas Medicine, Inc. (EDIT)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII: 4G7DT7PP3L

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03872479	Phase 1/2	Leber Congenital Amaurosis 10	Unknown	EDIT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Eye Diseases, HereditaryEye Disorders CongenitalInherited Retinal DystrophiesLeber Congenital Amaurosis 10Retinal DegenerationRetinal DiseaseVision Disorders

Sources

ClinicalTrials.gov NCT03872479

Updated Oct 3, 2026. Something wrong or missing? Report it on the EDIT page.

Follow EDIT, the company behind EDIT-101

See EDIT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

EDIT catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z